Mergers and Acquisitions Takeover Bids

  • Gabelli eyes takeover targets

    Mario Gabelli, Gamco Investors chairman & CEO, explains why he is watching shares of Protective Life, Interpublic Group, and Hillshire Brands.

  • Cramer: Many reasons to own Tyson

    Tyson Foods is jumping in the takeover battle for Hillshire. The "Squawk on the Street" news team discuss Tyson's $50 a share offer.

  • 2014: Best M&A year ever?

    This year has been the year of mergers, acquisitions and hostile takeovers. Attorney Frank Aquila, Sullivan & Cromwell, discusses what's behind the recent M&A boom.

  • Cramer: Hillshire needs to buy Birds Eye

    The "Squawk on the Street" take a close look at the offer from Pilgrim's Pride for Hillshire Brands. Pilgrim's Pride wants Hillshire to drop Pinnacle Foods of which Birds Eye Foods is a brand.

  • Cramer: Allergan needs Valeant deal

    CNBC's David Faber and Jim Cramer discuss the latest M&A action, including Valeant Pharmaceuticals raising its takeover bid for Allergan, and GE improving its offer for France's Alstom.

  • Hillshire responds to Pilgrim's Pride takeover offer

    CNBC's Dominic Chu reports Hillshire Brands has responded to the proposal by Pilgrim's Pride to acquire Hillshire for about $6.4 billion

  • Hillshire gets takeover offer from Pilgrim's Pride

    The "Squawk on the Street" news team discusses the report that Pilgrim's Pride is offering to acquire Hillshire Brands for $6.4 billion.

  • Cramer eyes food fight

    Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell. Today Cramer shares his thoughts on Pilgrim Pride's bid for Hillshire Brands.

  • Pfizer drops bid for AstraZeneca

    John Eade, Argus Research, discusses Pfizer's likely next move after abandoning its attempt to buy AstraZeneca. There's a good chance AstraZeneca management could ask Pfizer to come back to the table, says Eade.

  • Pfizer's final bid rejected

    $117 billion was not enough for AstraZeneca. CNBC's Meg Tirrell looks at Pfizer and AstraZeneca's stocks.

  • Next big takeover

    CNBC's Herb Greenberg plays a game of "deal or no deal" and rounds up potential next takeover targets.

  • Faber Report: Hillshire to acquire Pinnacle

    CNBC's David Faber reports Hillshire Brands is buying Pinnacle Foods. And Faber comments on Allergan's rejection of Valeant's takeover bid.

  • What Cramer expects from IPO market

    Allergan has rejected a $47 billion takeover bid by Valeant Pharmaceuticals. The "Squawk on the Street" news team discuss m&a in pharmaceuticals and the IPO market.

  • Ackman: Makes sense to be partners with Icahn instead of enemies

    Bill Ackman, Pershing Square Capital Management, explains what led him to reach out to activist investor Carl Icahn. Ackman calls him "a charming guy."

  • Ackman: Allergan, Valeant merger economically right thing to do

    Bill Ackman, Pershing Square Capital Management, weighs in on the Valeant and Allergan controversy and long-term shareholder activism.

  • Ackman: No alternative to Fannie and Freddie

    CNBC's Scott Wapner speaks to Bill Ackman, Pershing Square Capital Management, about the "winding down" of the old version of Fannie and Freddie and discusses the importance of reform to their programs.

  • AstraZeneca rejects new Pfizer bid

    AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.

  • Pfizer CEO Ian Read recently met with U.K.-based investors to discuss a second bid for AstraZeneca, valuing the firm at $106 billion, sources said.

  • GE's Immelt: Alstom deal will be executed

    Alstom has until June 2 to review General Electric's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.

  • GE's big bid for Alstom

    Alstom is accepting GE's $13.5 billion bid for its energy assets, reports CNBC's Mary Thompson.